EGFR and prostate cancer: According to western blot data reported by Han et al., (S)-2-{[5-[1-(6-methoxynaphtalene-2-yl)ethyl]-4-(4-fluorophenyl)-4H-1,2,4-triazole-3-yl]thio}-N′-[(5-nitrofuran-2-yl)methylidene]acetohydrazide caused a significant decrease in the epidermal growth factor receptor (EGFR), PI3K, and Akt phosphorylation in PC3 human prostate cancer cells [32].